Search results for "Multimodality Therapy"

showing 3 items of 3 documents

Childhood cancer:Survival, treatment modalities, late effects and improvements over time

2021

Since the 1960s, paediatric oncologists have gradually become better organised in large study groups and participation in clinical trials is today considered as the standard of care, with most children with cancer in Europe and North America being enrolled on available treatment protocols. Chemotherapy is nowadays the main element of therapy, but irradiation is still required for some patients. With the advent of multimodality therapy and supportive care, five-year cancer survival exceeds 80 % in most European and North American countries today. The substantial improvements in survival led to a constantly growing population of childhood cancer survivors. Concerns regarding the risk of late …

Cancer Researchmedicine.medical_specialtyTime FactorsSurvivalEpidemiologyPopulationMultimodality TherapySurvivorshipSocial and socioeconomic conditions03 medical and health sciencesSomatic late effects0302 clinical medicineQuality of life (healthcare)NeoplasmsSurvivorship curvemedicineHumans030212 general & internal medicineChild610 Medicine & healthIntensive care medicineeducationSocioeconomic statusClinical Trials as Topiceducation.field_of_studybusiness.industryCancerTemporal changesmedicine.diseaseCombined Modality TherapySurvival AnalysisMental healthSurvivor cohortsEuropeClinical trialTreatment OutcomeOncology030220 oncology & carcinogenesisCancer treatmentNorth AmericaMental late effectsbusinessChildhood cancer360 Social problems & social services
researchProduct

Damage to the urinary tract secondary to irradiation.

1995

During the past two decades, highly effective multimodality therapy with surgery, chemotherapy and irradiation has been developed through consecutive national and international study protocols for childhood genitourinary cancers, the model being Wilms' tumor. These studies represent a landmark achievement in the history of pediatric oncology and mark the success of multi-institutional efforts. Now that excellent survival rates have been established, current interest is now directed primarily at examination of survivors for long-term treatment complications and minimizing the side effects while preserving treatment efficacy. Treatment sequelae may not become evident until many years after th…

NephrologyChemotherapymedicine.medical_specialtyPediatricsbusiness.industryGenitourinary systemUrologymedicine.medical_treatmentUrinary systemCancerMultimodality Therapymedicine.diseaseWilms TumorKidney NeoplasmsSurgeryRadiation therapyInternal medicineRhabdomyosarcomaMedicineHumansbusinessRhabdomyosarcomaChildRadiation InjuriesUrinary TractWorld journal of urology
researchProduct

Serum microRNA profiles as prognostic/predictive markers in the multimodality therapy of locally advanced adenocarcinomas of the gastroesophageal jun…

2014

Neoadjuvant multimodality treatment is frequently applied to improve the poor prognosis of locally advanced adenocarcinomas of the gastroesophageal junction. This study aimed to asses if serum microRNA profiles are useable as response indicators in this therapeutic setting. Fifty patients with locally advanced adenocarcinomas of the gastroesophageal junction were included in the study. All patients received neoadjuvant therapy and subsequently underwent surgical resection. Histomorphologic regression was defined as major histopathological response when resected specimens contained less than 10% vital residual tumor cells. Circulating RNA was isolated from pretherapeutic/post-neoadjuvant blo…

OncologyCancer ResearchPathologymedicine.medical_specialtyMicroarraybusiness.industrymedicine.medical_treatmentRetrospective cohort studyMultimodality TherapyGene expression profilingBlood serumOncologyInternal medicinemicroRNAMedicinebusinessNeoadjuvant therapyChemoradiotherapyInternational Journal of Cancer
researchProduct